CRINETICS PHARMACEUTIC

56.09

25-November-24 16:00:09

15 minutes delayed

Stocks

+0.03

+0.05%

Today's range

55.93 - 57.42

ISIN

N/A

Source

NASDAQ

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

24 Mar 2021 07:10:00 By Nasdaq GlobeNewswire
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

22 Mar 2021 07:10:00 By Nasdaq GlobeNewswire
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

12 Mar 2021 07:10:00 By Nasdaq GlobeNewswire
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

04 Feb 2021 07:10:00 By Nasdaq GlobeNewswire
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

03 Feb 2021 07:10:00 By Nasdaq GlobeNewswire
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

06 Jan 2021 07:05:00 By Nasdaq GlobeNewswire

<<
<
3
4
5
6
7
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.